报价延迟最少15分钟:2026/11/06 15:20 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.3134 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.87/-0.51
|
|
企业价值
7.85M
|
| 资产负债 |
|
每股账面净值
0.04
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion. |
